Table 3:

PP2A inhibition by LB100 in combination with cytotoxic chemotherapy or radiation.

Reference	Cancer	Combination Therapy	Major Findings In addition to enhanced tumor growth inhibition with combination therapy vs. radiation / chemotherapy alone
Lu et al. PCNA 2009	Glioblastoma Neuroblastoma	Temozolamide Doxorubicin	Combination therapy induced tumor regression and prevented recurrence in 50% of animals Prevented DNA damage-induced S-phase arrest; cells progress to mitosis and are susceptible to irregular replication and mitotic catastrophe
Zhang et al. Biomaterials 2010	Sarcoma	Doxorubicin	Reduced incidence of lung metastasis
Martiniova et al. PLoS One 2011	Pheochromocytoma	Temozolamide	Delayed tumor recurrence, prolonged disease-free survival in 40% of animals that had developed intra-hepatic metastases
Wei et al. Clin Cancer Res 2013	Pancreatic Cancer	Radiation	LB100-mediated radio-sensitization was specific to pancreatic cancer cells vs. normal colonic epithelial cells HRR in response to DNA damage was also inhibited LB100-induced signaling alterations were consistent with those induced by si-PPP2R1A
Bai et al. Mol Cancer Ther 2014	Hepatocellular Carcinoma	Doxorubicin Cisplatin	Reported increased angiogenesis and vascular permeability, which enhanced drug penetration but may also create potential for metastasis
Lv et al. Oncotarget 2014	Nasopharyngeal Carcinoma	Radiation	LB100 was capable of radio-sensitizing a previously resistant cell line
Bai et al. Cancer Letters 2014	Pancreatic Cancer	Doxorubicin	Increased blood vessel density allowed for enhanced blood perfusion and doxorubicin drug concentration in tumor tissue; was linked to HIF-1α expression and increased VEGF secretion
Zhang et al. Cell Cycle 2015	Osteosarcoma	Cisplatin	Reduced incidence of lung metastases
Chang et al. Mol Cancer Ther 2015	Ovarian Carcinoma	Cisplatin	Delayed tumor burden in an intraperitoneal metastasis model and prevented tumor relapse PP2A-C knockdown also sensitized cells to cisplatin
Gordon et al. Mol Cancer Ther 2015	Glioblastoma	Radiation	In contrast to some reports, mitotic catastrophe was a major cell death mechanism with combination therapy, while apoptosis was minimally observed
Ho et al. Oncotarget 2016	Medulloblastoma	Cisplatin	LB100 decreased cell motility and in vivo invasiveness, tumors for both combination and LB100 monotherapy displayed well-demarcated borders LB100 has anti-tumor activity through STAT3 inhibition and altered subcellular localization
Fu et al. Tumor Biol 2016	Hepatocellular Carcinoma	Sorafenib	LB100 activity was linked to hypoxic environments, where apoptosis occurred subsequent to Smad3 hyperphosphorylation and Bcl2 inhibition
Hu et al. Sci Rep 2017	Acute Myeloid Leukemia	Daunorubicin	Bcl2 upregulation is a hallmark of the syndrome. LB100 increased miR-181b which inhibited Bcl2 to induce apoptosis
Hao et al. Neuro Oncol 2017	Chordoma	Radiation	LB100 reduced tumor cell mobility and invasiveness both without and with radiation co-treatment
Lai et al. Sci Transl Med 2018	BCR-ABL+ Leukemia	Imatinib	PP2A inhibition was able to re-sensitize TKI non-responding cells, and also demonstrated success in targeting stem cell populations
Ho et al. Cancer Letters 2018	Meningioma	Radiation	Also linked LB100 anti-tumor growth activity to inhibited STAT3 signaling